This website uses cookies. By using the site you are agreeing to our Privacy Policy.



Signing of a Memorandum on Clinical Development of Anti-Influenza Virus Drug in China

Developing a therapy for serious influenza patients using the active ingredient of AVIGAN® Tablets

October 26, 2018

FUJIFILM Corporation (President: Kenji Sukeno) signed a memorandum on October 25 with Zhejiang Hisun Pharmaceutical Co., Ltd. (Chairman: Bai Hua, HISUN, hereafter) one of the leading Chinese pharmaceutical companies, the China-Japan Friendship Clinic, and the National Engineering Research Center for the Emergency Drug on the clinical development of an anti-influenza virus drug in China. This clinical development seeks to develop a therapy for the treatment of serious influenza patients using the active ingredient of AVIGAN® Tablets, which have already acquired Japan's manufacturing and marketing approval as an anti-influenza virus drug. Going forward, Fujifilm will support this clinical development by providing clinical data on AVIGAN.

[ Content of the Memorandum ]

  • Fujifilm will provide accumulated clinical data on AVIGAN to HISUN, the China-Japan Friendship Clinic, and the National Engineering Research Center for the Emergency Drug.
  • The China-Japan Friendship Clinic and the National Engineering Research Center for the Emergency Drug will conduct clinical development targeting serious influenza patients.
  • HISUN will aim to acquire manufacturing and marketing approval in China for an anti-influenza virus drug with the same active ingredient as AVIGAN.
  • Fujifilm and HISUN will consider the development of an injection for serious influenza patients with the active ingredient of AVIGAN.

If administration of drugs to patients is delayed or if a patient with a chronic illness develops influenza, there are cases where it becomes serious and leads to death. In China, infection with a highly virulent form of the influenza virus leading to death has been reported. Currently, there is no established treatment for influenza patients with serious cases of influenza, and there is an increasing need for development.
Fujifilm acquired Japan's manufacturing and marketing approval* for the anti-influenza virus drug AVIGAN in 2014. AVIGAN has a mechanism where it prevents the proliferation of the virus by inhibiting the gene replication of the virus within the cells, and has been confirmed to have antiviral properties against various avian influenza viruses in laboratory animals. Fujifilm has given HISUN, which was interested in the characteristics and future potential of AVIGAN, the right to develop, manufacture, and market an anti-influenza virus drug in China using patents** related to the active ingredient of AVIGAN.
Based on the memorandum signed today, Fujifilm will support the clinical development of an anti-influenza virus drug in China going forward, while also seeking to take the treatment developed through this clinical development to countries other than China in partnership with HISUN, the China-Japan Friendship Clinic, and the National Engineering Research Center for the Emergency Drug.

Fujifilm will work to provide solutions to the threat of infectious diseases and contribute to the further enhancement of the quality of healthcare and maintenance and enhancement of people's health.

  • * Manufacturing and marketing approval acquired by FUJIFILM Toyama Chemical Co., Ltd.
  • ** Including the substance patent and use patent for “Favipiravir”, the active ingredient of “AVIGAN”.

For inquiries on information in this media release, contact:

Media Contact:
Corporate Communications Division
TEL :+81-3-6271-2000
Other Inquiries:
Pharmaceutical Products Division
TEL :+81-6271-2171